Professor John Lusingu
Professor John Lusingu received his Ph.D. degree in health sciences from the University of Copenhagen, Denmark in 2006 focusing on epidemiology and immunity of malaria. He completed his medical degree (MD) in 1994 from the University of Dar es Salaam, Tanzania. He worked as a General Practitioner in the southern highlands of Tanzania for five years and in 2000, he joined National Institute for Medical Research (NIMR) with a focus of studying malaria immunity. He conducted several field based studies to evaluate malaria epidemiology and later on joined University of Copenhagen, Denmark under Gates Malaria Partnership consortium where he pursued his Ph.D. Professor John Lusingu is a Principal Research Scientist of the NIMR and he is also a Professor of the University of Copenhagen, Denmark with extensive experience in field studies including basic malaria research and clinical trials of malaria drugs and vaccines through phases 1, 2 and 3. He completed extension of the Phase 3 study of the RTS,S/AS01 malaria vaccine manufactured by GSK and sponsored by PATH-MVI and Bill & Melinda Gates Foundation. He is an overall Principal Investigator of IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine (SP) resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial (TRIA-2015-1076-IMPROVE)” Clinical Trial Tanzania sites of Korogwe and Handeni districts and a Senior Fellow of EDCTP2 funded Project on Malaria Research and Capacity building for field trials in Tanzania (MaReCa). He has co-authors 100 peer-reviewed articles as per PubMed. Currently, Prof. John Lusingu is the Acting Director of NIMR Tanga Centre.
His main interest is prevention of malaria in children and pregnancy associated malaria.